Litcius/Paper detail

NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis

Renchen Ji, Yuan Wang, Deyue Pan, Jian Han, Y Wang, Shuo Zheng, Wenzhi Zhao, Xiaojie Li, Chuanchun Han, Lu Zhang, Lu Zhang

2024Cancer Letters15 citationsDOI

Topics & Concepts

OsteosarcomaCancer researchTumor microenvironmentBiologyTumor progressionChemokineIn vivoProgrammed cell deathInterleukin 8Cell biologySignal transductionChemistryImmunologyImmune systemCancerInflammationApoptosisBiochemistryTumor cellsBiotechnologyGeneticsUbiquitin and proteasome pathwaysCAR-T cell therapy researchinterferon and immune responses
NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis | Litcius